Paclitaxel 100mg Injection: Storage, Handling, and Safety Information

Paclitaxel 100mg Injection is a cytotoxic anticancer medicine that requires controlled storage, professional preparation, and strict hazardous-drug precautions.

A commonly supplied conventional formulation contains 100 mg of paclitaxel in a 16.7 mL multidose vial, equivalent to a concentration of 6 mg/mL. It is a nonaqueous concentrate that must be diluted with a compatible intravenous fluid before infusion. icine should not be stored, prepared, diluted, or administered like an ordinary injectable product. It should be handled only by trained healthcare professionals operating under an approved chemotherapy protocol.

The exact instructions on the manufacturer’s carton and package insert always take priority. Storage conditions, excipients, in-use stability, container compatibility, and preparation requirements can differ between manufacturers and formulations.

Important Formulation Difference

The information in this guide primarily applies to conventional paclitaxel injection concentrate, typically supplied at 6 mg/mL.

It should not automatically be applied to:

• Paclitaxel protein-bound particles for injectable suspension
• Albumin-bound paclitaxel
• Liposomal paclitaxel formulations
• Investigational paclitaxel products
• Products with a different concentration or excipient system

Albumin-bound paclitaxel is supplied as a powder for suspension and follows different reconstitution and administration instructions. It is not interchangeable with conventional paclitaxel concentrate on a milligram-for-milligram basis unless specifically directed by the treating oncology team. Storage and Handling Summary

Item	General requirement for conventional paclitaxel concentrate
Common vial strength	100 mg in 16.7 mL
Concentration	6 mg/mL
Routine storage	20°C to 25°C
Light protection	Keep in the original carton
Refrigeration required	No, unless the specific label states otherwise
Dilution required	Yes, before intravenous infusion
PVC equipment	Plasticized PVC is generally not recommended
Recommended containers	Glass, polypropylene, or polyolefin
Infusion filter	Microporous in-line filter no greater than 0.22 micron
Handling classification	Hazardous antineoplastic drug
Preparation location	Controlled professional healthcare environment

These points are based on a representative US prescribing label. Institutions must verify the exact manufacturer’s instructions before handling any vial. hould Paclitaxel 100mg Injection Be Stored?

Store Unopened Vials at Controlled Room Temperature

A representative Paclitaxel Injection USP label instructs users to store unopened vials between:

20°C and 25°C, or 68°F and 77°F

The vial should remain in its original carton until it is needed. The carton protects the medicine from light and helps preserve the manufacturer’s labeling, lot number, expiration date, and handling instructions. le storage area should be:

• Secure
• Access-controlled
• Clean and dry
• Protected from direct sunlight
• Monitored for temperature excursions
• Clearly identified for hazardous drugs
• Separated according to the facility’s hazardous-drug policy

Paclitaxel should not be stored in an unrestricted public area, household medicine cabinet, food refrigerator, or any location accessible to children or untrained personnel.

Protect the Vial From Light

The vial should remain inside the original carton until use.

Avoid leaving it:

• Under direct sunlight
• Near a window
• Under intense heat-producing lights
• In an unmonitored vehicle
• Beside heating or cooling equipment
• Outside the pharmacy’s controlled storage area

Light protection is part of the labeled storage requirement for conventional paclitaxel concentrate. Paclitaxel Need Refrigeration?

Routine refrigeration is generally not required for the conventional 6 mg/mL formulation discussed in this article.

The cited label states that refrigeration or freezing does not adversely affect the stability of the unopened product. However, refrigeration may cause components in the vial to precipitate temporarily. These components may redissolve when the vial returns to room temperature with little or no agitation. s not mean that facilities should intentionally refrigerate or freeze the product.

The labeled routine storage condition remains 20°C to 25°C. Unnecessary refrigeration can create confusion, increase the possibility of condensation, and make visual inspection more difficult.

What Should Be Done if Precipitation Appears?

After a refrigerated vial returns to room temperature, temporary precipitate may redissolve.

The vial should be assessed by qualified pharmacy personnel before use.

According to the representative prescribing information:

• Temporary precipitation after refrigeration may resolve at room temperature.
• If the solution remains cloudy, it should not be used.
• If an insoluble precipitate remains, the vial should be discarded.
• Any decision must follow the manufacturer’s label and institutional policy. ould not attempt to correct persistent cloudiness through aggressive shaking, heating, improvised filtration, or unapproved manipulation.

Safe Transportation and Receiving

Because paclitaxel is a hazardous antineoplastic drug, safety precautions begin before the vial enters the pharmacy.

The 2024 NIOSH hazardous-drug list includes paclitaxel as an antineoplastic hazardous drug with manufacturer special-handling information. sportation Requirements

Paclitaxel shipments should be packaged to minimize:

• Vial breakage
• Leakage
• Exposure to light
• Unauthorized access
• Temperature excursions
• Environmental contamination

Hazardous-drug packages should be transported in sealed, protective containers that reduce the possibility of breakage or leakage if dropped. Staff transporting hazardous drugs should receive spill-response training and have appropriate emergency procedures available. rnal shipping carton should not be opened casually in an office, sales area, patient room, or general storage space.

Receiving Inspection

Receiving staff should inspect the outer shipping carton before opening it.

Check for:

• Crushed corners
• Wet or stained packaging
• Broken seals
• Visible liquid
• Unusual odor
• Damaged temperature indicators
• Missing hazardous-drug identification
• Incorrect product or strength

A damaged package should not be opened by untrained personnel.

OSHA guidance recommends that facilities establish procedures for damaged hazardous-drug shipments. Appropriate personal protective equipment and a spill kit should be available in receiving areas where such packages may be handled. aclitaxel Requires Hazardous-Drug Precautions

Paclitaxel is a cytotoxic medicine designed to interfere with cell division. The same pharmacological properties that make it useful in cancer treatment can present an occupational exposure risk to workers who receive, compound, transport, administer, clean, or dispose of it.

Possible occupational exposure routes include:

• Skin contact
• Eye or mucous-membrane contact
• Accidental injection
• Inhalation of droplets or aerosols
• Contact with contaminated surfaces
• Handling leaking vials or infusion equipment
• Cleaning spills
• Handling contaminated waste

NIOSH identifies workers involved in handling, preparation, administration, and disposal as potentially exposed groups. nal Protective Equipment

The exact PPE requirement depends on the activity and the institution’s risk assessment.

For professional handling, facilities may require:

• Tested chemotherapy gloves
• A disposable protective gown
• Eye and face protection when splashing is possible
• Shoe or sleeve covers for certain procedures
• Respiratory protection for spills that may generate aerosols
• A second pair of chemotherapy gloves during higher-risk procedures

OSHA guidance discusses double-gloving, protective gowns, proper handwashing, and additional protection for spill cleanup. Gloves should be removed carefully so contaminated outer surfaces do not contact bare skin or clean surfaces. examination gloves may not provide the same tested protection as chemotherapy-rated gloves.

Professional Preparation and Dilution

Paclitaxel Concentrate Must Be Diluted

Conventional Paclitaxel Injection USP is not administered directly from the vial.

A representative label permits dilution with:

• 0.9% Sodium Chloride Injection
• 5% Dextrose Injection
• 5% Dextrose with 0.9% Sodium Chloride Injection
• 5% Dextrose in Ringer’s Injection

The labeled final concentration is 0.3 to 1.2 mg/mL for the cited formulation. ormation is intended for licensed healthcare professionals. It is not a home-preparation instruction.

The patient-specific dose, infusion duration, premedication, diluent volume, and treatment schedule must be determined by the prescribing oncology team.

Preparation Must Follow Sterile Compounding Standards

Paclitaxel preparation should take place in a designated professional environment using:

• Aseptic technique
• Hazardous-drug engineering controls
• Appropriate PPE
• Approved pharmacy procedures
• Properly trained and competent personnel
• Clearly labeled final containers
• Documented dose verification
• Spill-control procedures

A closed-system drug-transfer device may be incorporated according to institutional policy and applicable standards. OSHA defines such a device as one designed to prevent environmental contaminants from entering the system and hazardous drug or vapor from escaping. lasticized PVC Should Be Avoided

The vehicle used in conventional paclitaxel concentrate can cause the plasticizer DEHP to leach from plasticized PVC containers and administration sets.

The amount of extractable DEHP can increase with contact time and paclitaxel concentration.

For that reason, the cited label recommends preparing and storing diluted paclitaxel in:

• Glass containers
• Polypropylene containers
• Polyolefin containers

Non-PVC administration sets, such as polyethylene-lined sets, should be used. ould check the complete fluid pathway, not only the infusion bag. Tubing, connectors, filters, transfer devices, and other components should be evaluated for compatibility.

In-Line Filter Requirement

Conventional paclitaxel should be administered through an in-line filter with a microporous membrane no greater than 0.22 micron, according to the cited product label. er does not replace:

• Visual inspection
• Aseptic preparation
• Correct dilution
• Compatible containers
• Proper infusion tubing
• Patient monitoring

A filter should never be used to “repair” a solution containing unexplained particles or persistent precipitate.

Stability After Dilution

For the representative formulation reviewed here, properly prepared infusion solutions are described as physically and chemically stable for up to 27 hours at approximately 25°C under room-lighting conditions. chemical stability is not the same as guaranteed microbiological safety.

The usable period may be shorter because of:

• The preparation environment
• Aseptic processing requirements
• Institutional beyond-use dating
• Local regulations
• Container type
• Manufacturer-specific labeling
• Storage conditions after preparation

The pharmacy must assign the final beyond-use time. Users should not automatically apply the 27-hour figure to every paclitaxel product.

Visual Inspection Before Administration

Before use, qualified personnel should inspect the solution and container whenever possible.

Check for:

• Unexpected discoloration
• Persistent cloudiness
• Visible particles
• Cracks or leaks
• Damaged seals
• Incorrect labeling
• Incorrect concentration
• Expired dating
• Evidence of improper storage

Some diluted paclitaxel solutions may appear slightly hazy because of the formulation vehicle. This expected appearance should still be differentiated from abnormal particulate matter or persistent precipitation using the manufacturer’s instructions. re is uncertainty, the product should be quarantined and assessed by the pharmacy rather than administered.

Administration Safety

Paclitaxel should be administered only under the supervision of a physician experienced in cancer chemotherapy and in a facility equipped to manage serious complications. t clinical risks include:

• Severe hypersensitivity reactions
• Bone-marrow suppression
• Peripheral neuropathy
• Cardiovascular effects
• Injection-site reactions
• Extravasation
• Infection related to neutropenia

The prescribing information advises close monitoring of the infusion site for possible infiltration. commonly receive premedication according to the selected paclitaxel formulation and treatment protocol. Premedication and monitoring requirements should never be copied from another patient’s treatment plan.

What to Do After Accidental Exposure

Skin Contact

If paclitaxel solution contacts the skin:

1. Stop the handling activity.
2. Remove contaminated gloves or clothing.
3. Wash the affected skin immediately and thoroughly with soap and water.
4. Follow the facility’s exposure-reporting procedure.
5. Obtain occupational health or medical evaluation when required.

The product label reports that topical exposure has been associated with tingling, burning, and redness. or Mucous-Membrane Contact

Affected mucous membranes should be flushed thoroughly with water.

The incident should be reported immediately according to the facility’s emergency procedure. Medical evaluation may be necessary.

Inhalation or Aerosol Exposure

Personnel should leave the contaminated area when safe to do so and activate the facility’s hazardous-drug response procedure.

The cited label reports symptoms following inhalation exposure, including breathing difficulty, chest discomfort, eye irritation, sore throat, and nausea. Management

Every area where paclitaxel is received, stored, prepared, transported, or administered should have access to an appropriate hazardous-drug spill kit.

A spill kit may contain:

• Chemotherapy gloves
• Protective garments
• Eye and face protection
• Absorbent spill pads
• Disposable towels
• Hazardous-waste bags
• A puncture-resistant sharps container
• Equipment for collecting broken glass
• Respiratory protection where required

Only trained personnel wearing appropriate PPE should clean a paclitaxel spill.

OSHA guidance recommends assessing the spill, restricting the area, obtaining a spill kit, containing the liquid, collecting broken glass safely, cleaning according to the facility’s decontamination procedure, and disposing of contaminated materials as hazardous-drug waste. al mask is not considered adequate respiratory protection for an aerosol-producing hazardous-drug spill. Respirator use requires an appropriate respiratory-protection program.

Safe Disposal

Unused paclitaxel, partially used vials, contaminated tubing, gloves, absorbent materials, and spill-cleanup supplies should not be placed in ordinary household or office waste.

Disposal must comply with:

• Facility hazardous-drug procedures
• Pharmaceutical-waste requirements
• Environmental regulations
• Local and national laws
• Licensed waste-contractor requirements

Needles and broken vials must be placed in an appropriate puncture-resistant hazardous-waste container.

Unused product should not be:

• Poured into a sink
• Flushed down a toilet
• Placed in general recycling
• Returned through ordinary mail without authorization
• Taken home by staff or patients
• Mixed with regular clinical waste unless permitted by policy

Practical Safety Scenarios

Scenario 1: A Refrigerated Vial Shows Crystals

A pharmacy receives a conventional paclitaxel vial that was exposed to refrigeration.

The vial is kept inside its carton and allowed to reach room temperature under controlled conditions. The precipitate disappears with little or no agitation.

The pharmacist then verifies the product against the package insert before releasing it.

If cloudiness or insoluble material remains, the vial is quarantined and discarded or returned according to policy.

Scenario 2: The Shipping Carton Is Wet

Receiving staff notice a wet area and chemical odor on a paclitaxel shipment.

They do not open the carton at the general receiving desk.

The area is restricted, trained hazardous-drug personnel are contacted, appropriate PPE is used, and the package is contained according to the facility’s damaged-shipment procedure.

Scenario 3: A PVC Infusion Bag Is Selected

During verification, the pharmacist identifies that a plasticized PVC container was selected for conventional paclitaxel.

Preparation is stopped before administration. A compatible glass, polypropylene, or polyolefin container and a non-PVC administration set are selected according to the product label.

This prevents unnecessary patient exposure to leached DEHP.

Frequently Asked Questions

Can Paclitaxel 100mg Injection Be Stored in a Refrigerator?

Conventional 6 mg/mL paclitaxel is normally stored at 20°C to 25°C in its original carton. Refrigeration is not routinely required.

Always follow the exact manufacturer’s label.

Is Paclitaxel 100mg Ready to Inject?

No. Conventional Paclitaxel Injection is a concentrate that must be diluted before intravenous infusion by trained professionals.

It must not be injected directly from the vial.

Can Paclitaxel Be Prepared at Home?

No. Paclitaxel is a hazardous cytotoxic medicine requiring professional sterile preparation, compatible equipment, protective controls, dose verification, and medical supervision.

Can a Cloudy Paclitaxel Vial Be Used?

A refrigerated vial may show temporary precipitation that resolves at room temperature. If the solution remains cloudy or contains insoluble precipitate, it should not be used.

Is Paclitaxel the Same as Albumin-Bound Paclitaxel?

No. They have different formulations and preparation requirements.

The label for one product should not be used as the preparation guide for another.

How Long Is Diluted Paclitaxel Stable?

One representative conventional formulation states that properly prepared infusion solutions are physically and chemically stable for up to 27 hours at approximately 25°C under room lighting.

The actual beyond-use time must be assigned by the pharmacy based on the exact product, preparation conditions, sterile-compounding requirements, and local policy. Safety Checklist

Before storing or using Paclitaxel 100mg Injection, healthcare personnel should confirm:

• The exact formulation and manufacturer
• The vial strength and concentration
• The labeled storage range
• Protection from light
• Product integrity
• Expiration date
• Hazardous-drug identification
• Required PPE
• Compatible diluent
• Correct final concentration
• Non-PVC container and tubing requirements
• Required in-line filter
• Assigned beyond-use time
• Spill-response readiness
• Hazardous-waste disposal route
• Patient-specific prescription and verification

Conclusion

Paclitaxel 100mg Injection requires much more than ordinary room-temperature storage.

The conventional 100 mg/16.7 mL concentrate is generally stored at 20°C to 25°C, protected from light, and retained in its original carton. It must be diluted professionally, prepared with compatible non-PVC equipment, administered through an appropriate in-line filter, and handled as a hazardous antineoplastic drug. agement depends on trained personnel, controlled pharmacy procedures, suitable protective equipment, careful visual inspection, documented temperature control, and immediate access to spill-response resources.

This article provides general educational information. It does not replace the product-specific prescribing information, institutional chemotherapy procedures, or instructions from a licensed oncologist or pharmacist.

Continue reading: More Cancer Drug Guidelines

How to Check Paclitax Nab Injection Packaging, Batch Number, and Expiry Date

Paclitax Nab Injection 100mg: Product Details, Uses, and Doctor-Supervised Administration

Abiraterone Acetate 250mg: Product Details and Doctor-Supervised Use

Bortezomib 3.5mg Injection: Handling, Storage and Safety Information